FDA approves Vertex's Casgevy for children as young as 2, opening door to thousands more patients

Vertex Pharmaceuticals has won expanded FDA approval for gene therapy Casgevy, clearing children as young as 2 with sickle cell disease or transfusion-dependent beta thalassemia for the one-time treatment — a decision that makes roughly 5,500 additional children in the US newly eligible.